Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 11:10AM ET
7.34
Dollar change
+0.25
Percentage change
3.55
%
Index- P/E- EPS (ttm)-0.38 Insider Own0.38% Shs Outstand69.39M Perf Week-9.77%
Market Cap510.72M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float69.31M Perf Month-17.34%
Income-26.29M PEG- EPS next Q-0.34 Inst Own0.65% Short Float0.11% Perf Quarter-7.32%
Sales165.81M P/S3.08 EPS this Y103.85% Inst Trans- Short Ratio7.25 Perf Half Y-31.78%
Book/sh2.95 P/B2.49 EPS next Y-1483.43% ROA-4.44% Short Interest0.08M Perf Year-46.62%
Cash/sh2.74 P/C2.68 EPS next 5Y- ROE-12.32% 52W Range6.58 - 17.05 Perf YTD-29.21%
Dividend Est.- P/FCF- EPS past 5Y- ROI-6.48% 52W High-56.95% Beta2.19
Dividend TTM- Quick Ratio2.22 Sales past 5Y31.63% Gross Margin35.80% 52W Low11.55% ATR (14)0.44
Dividend Ex-Date- Current Ratio2.64 EPS Y/Y TTM85.07% Oper. Margin-71.32% RSI (14)38.52 Volatility5.16% 4.36%
Employees676 Debt/Eq1.12 Sales Y/Y TTM-56.74% Profit Margin-15.86% Recom1.20 Target Price20.16
Option/ShortNo / Yes LT Debt/Eq0.99 EPS Q/Q427.43% Payout- Rel Volume1.69 Prev Close7.09
Sales Surprise-50.97% EPS Surprise-21.11% Sales Q/Q-1.12% EarningsMay 07 BMO Avg Volume10.47K Price7.34
SMA20-12.72% SMA50-9.62% SMA200-24.41% Trades Volume5,187 Change3.55%
Date Action Analyst Rating Change Price Target Change
Aug-03-22Initiated H.C. Wainwright Buy $34
Jun-05-24 01:00AM
Jun-04-24 12:00PM
11:35AM
Jun-03-24 11:35AM
May-31-24 11:35AM
01:00AM Loading…
May-21-24 01:00AM
May-13-24 08:53AM
01:00AM
May-07-24 01:00AM
May-06-24 01:30AM
Apr-04-24 12:00PM
Mar-26-24 02:00AM
Mar-25-24 02:00AM
Mar-21-24 11:06AM
02:00AM
02:00AM Loading…
Mar-20-24 02:00AM
Mar-18-24 02:00AM
Mar-06-24 02:30AM
Mar-04-24 01:00AM
Feb-29-24 01:00AM
Feb-15-24 01:00AM
Feb-07-24 02:30AM
Feb-05-24 01:00AM
Jan-10-24 01:00AM
Jan-05-24 02:30AM
Jan-04-24 11:45AM
Dec-29-23 04:30PM
Dec-20-23 11:45AM
Dec-06-23 02:30AM
Dec-04-23 04:20PM
01:00AM Loading…
01:00AM
Nov-27-23 01:00AM
Nov-15-23 01:30AM
Nov-13-23 01:00AM
Nov-11-23 10:25AM
Nov-10-23 01:00AM
Nov-09-23 01:00AM
Nov-07-23 01:00AM
Nov-06-23 02:30AM
Oct-25-23 12:15PM
Oct-11-23 11:45AM
Oct-05-23 02:30AM
Sep-27-23 09:33AM
Sep-25-23 01:00AM
Sep-21-23 01:00AM
Sep-07-23 01:00AM
Sep-06-23 02:30AM
Aug-31-23 01:00PM
Aug-29-23 01:00AM
Aug-28-23 01:00AM
Aug-17-23 01:00AM
Aug-14-23 01:00AM
Aug-03-23 02:30AM
Jul-05-23 02:30AM
Jun-22-23 01:00AM
Jun-21-23 12:15PM
Jun-13-23 01:00AM
Jun-07-23 02:00AM
May-31-23 01:15AM
01:00AM
May-30-23 01:00AM
May-04-23 12:00PM
01:00AM
Apr-06-23 02:00AM
Mar-31-23 01:00AM
Mar-30-23 01:00AM
Mar-23-23 02:00AM
Mar-06-23 02:00AM
Mar-02-23 01:00AM
Mar-01-23 11:45AM
Feb-20-23 01:00AM
Feb-17-23 01:00AM
Feb-16-23 01:00AM
Feb-14-23 01:00AM
Feb-03-23 12:00PM
Jan-19-23 12:00PM
Jan-05-23 12:00PM
Dec-30-22 12:30PM
Dec-23-22 11:04AM
02:41AM
01:00AM
Dec-21-22 11:45AM
Dec-08-22 10:21AM
Dec-06-22 08:16AM
01:00AM
Dec-05-22 12:00PM
01:00AM
Dec-02-22 10:54AM
Dec-01-22 04:13PM
01:00AM
Nov-29-22 12:00PM
Nov-17-22 01:00AM
Nov-16-22 09:55AM
Nov-10-22 01:00AM
Nov-07-22 11:45AM
Nov-04-22 01:00PM
Oct-12-22 12:00PM
Oct-10-22 01:00AM
Oct-07-22 12:00PM
Oct-04-22 04:00PM
Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.